Live Preview
Tag didn’t load? Click here and let us know!Share this result
Previews are deleted daily. Get a permanent share link sent to your inbox:
Script
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>DIGIFab - Clinical Monitoring Opportunity</title>
<style>
body {
margin: 0;
padding: 0;
font-family: sans-serif;
display: flex;
align-items: center;
height: 90px;
}
.container {
width: 720px;
display: grid;
grid-template-columns: 55px 1fr 200px; /* Adjusted to include space for scrolling box */
align-items: center;
height: 100%;
margin-left: 20px; /* Add more space between logo and container */
}
.logo {
width: 55px;
grid-row: 1;
margin: 4px 4px 0px 2px; /* Added small margins for logo */
}
.content {
grid-row: 1;
display: flex;
flex-direction: column;
line-height: 1.1; /* No line spacing between elements */
margin: 0;
padding: 0; /* Remove default padding */
font-size: 11px;
}
.heading {
font-weight: bold;
margin: 0; /* Negative margin to eliminate spacing */
color: #014757; /* Use button color for emphasis */
}
.subheading {
font-weight: bold;
margin: 0; /* Negative margin to eliminate spacing */
}
.text {
margin: 0; /* Eliminate margin after text */
}
.button {
background-color: #014757;
color: white;
padding: 2px 5px; /* Set padding to accommodate text and avoid overflow */
border: none;
border-radius: 5px;
cursor: pointer;
text-decoration: none;
display: inline-block;
margin-top: 2px; /* Reduced margin before button */
white-space: nowrap; /* Prevent text wrapping within button */
overflow: hidden; /* Hide overflowing text */
text-overflow: ellipsis; /* Add ellipsis (...) if text overflows */
}
/* Styling for the scrolling indications box */
.scrolling-box {
grid-column: 3;
padding: 10px;
margin-left: 4px; /* Add small margin to separate from container */
border: 1px solid #ccc;
height: 90px; /* Adjust height as needed */
overflow-y: scroll; /* Enable vertical scrolling */
font-size: 11px; /* Match font size with advertisement */
}
.scrolling-box p,
.scrolling-box ul {
margin: 0;
padding: 0;
}
.scrolling-box ul {
padding-left: 20px; /* Indent unordered list items */
}
</style>
</head>
<body>
<div class="container">
<img class="logo" src="https://serb.com/wp-content/uploads/2022/09/SERB-logo-200x57-1.svg" alt="SERB Logo">
<div class="content">
<p class="heading">Clinical Monitoring Opportunity!</p>
<p class="subheading">Monitor Digoxin Levels for Patient Safety</p>
<p class="text">This patient is on digoxin. Monitoring levels (~6 hours post-dose) is crucial for early detection of life-threatening toxicities. Act now and verify digoxin levels are within therapeutic range to optimize patient care. Click to Learn More:</p>
<a href="https://digifab.health/en-us/digoxin-toxicity/potentially-fatal-digoxin-toxicity.html" class="button">Potentially Fatal Digoxin Toxicity | DIGIFab</a>
<p class="text">For full Prescribing Information, <a href="https://digifab.health/getmedia/f821face-fe6e-4105-8090-5b81816942f0/DigiFab-PI_P12011E_A4-Updated-June2017.pdf">click here</a></p>
<p class="text"><p align="right"><small>US-DGF-2400033</small></p>
</div>
<div class="scrolling-box">
<p><strong>INDICATIONS AND USAGE</strong></p>
<p>DIGIFab is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose, including:
</p>
<ul>
<li>Known suicidal or accidental consumption of fatal doses of digoxin: 10 mg or more of digoxin in healthy adults, or 4 mg (or more than 0.1 mg/kg) in healthy children, or ingestion of an amount that can cause steady state serum concentrations of ≥10 ng/mL;</li>
<li>Chronic ingestions causing steady-state serum digoxin concentrations >6 ng/mL in adults or 4 ng/mL in children;</li>
<li>Manifestations of life-threatening toxicity of digoxin overdose such as severe ventricular arrhythmias, progressive bradycardia, and second or third degree heart block not responsive to atropine, serum potassium levels exceeding 5.5 mEq/L in adults or 6 mEq/L in children with rapidly progressive signs and symptoms of digoxin toxicity.
</li>
</ul>
<br></br>
<p><strong>IMPORTANT SAFETY INFORMATION</strong></p>
<p>Warnings and Precautions:</p>
<ul>
<li>General: Suicidal ingestion may result from more than one drug. Consider toxic effects of other drugs or poisons in cases where signs and symptoms of digitalis toxicity are not relieved by administration of DIGIFab.</li>
<li>Rapid drop in serum potassium concentration may occur after treatment. Monitor frequently.</li>
<li>Patients with poor cardiac function may deteriorate secondary to the withdrawal of the inotropic action of digoxin by DIGIFab. Monitor frequently and provide additional inotropic support if needed. Postpone re-digitalization, if possible, until the Fab fragments have been eliminated; this may require several days or a week or longer in patients with impaired renal function.</li>
<li>Hypersensitivity Reactions: Anaphylaxis and hypersensitivity reactions are possible. Carefully monitor patients for signs and symptoms of an acute allergic reaction and if one occurs, stop the infusion and treat immediately with appropriate emergency medical care.</li>
<li>Patients with known allergies to sheep protein or those who have previously received intact ovine antibodies or Fab are particularly at risk for an anaphylactic reaction.
<li>Do not administer DIGIFab to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.
<li>Use of DIGIFab in Renal Failure: The elimination half-life of DIGIFab in renal failure has not been clearly defined. Monitor patients with severe renal failure who receive DIGIFab for a prolonged period for possible recurrence of toxicity. Monitoring of free (unbound) digoxin concentrations after the administration may be appropriate.
</li>
</ul>
<br></br>
<p><strong>Laboratory Tests</strong></p>
<ul><li>DIGIFab may interfere with digitalis immunoassay measurements. Thus, standard serum digoxin concentration measurements may be clinically misleading until the Fab fragments are eliminated from the body. This may take several days or a week or more in patients with markedly impaired renal function. If possible, obtain serum digoxin samples before DIGIFab administration to establish the level of serum digoxin at the time of diagnosis.
<li>The total serum digoxin concentration may rise precipitously following administration of DIGIFab, but this will be almost entirely bound to the Fab fragment and not able to react with receptors in the body.
</li>
</ul>
<br></br>
<p><strong>Adverse Reactions</strong></p>
<ul> <li>The most common adverse reactions (>7%) related to DIGIFab administration are worsening congestive heart failure (13%), hypokalemia (13%) and worsening atrial fibrillation (7%).
</li>
</ul>
<br><p>For full Prescribing Information, <a href="https://digifab.health/getmedia/f821face-fe6e-4105-8090-5b81816942f0/DigiFab-PI_P12011E_A4-Updated-June2017.pdf">click here</a>.</p></br>
<br><p>June 2017</p></br>
</div>
</div>
</body>
</html>
Landing Page
This ad does not have a landing page available
Network Timeline
Performance Summary
2
Requests
2
Domains
6KB
Transfer Size
16KB
Content Size
178.0ms
Dom Content Loaded
451.0ms
First Paint
657.0ms
Load Time
Domain Breakdown
Transfer Size (bytes)
Loading...
Content Size (bytes)
Loading...
Header Size (bytes)
Loading...
Requests
Loading...
Timings (ms)
Loading...
Total Time
Loading...
Content Breakdown
Transfer Size (bytes)
Loading...
Content Size (bytes)
Loading...
Header Size (bytes)
Loading...
Requests
Loading...